@article {Edwards2021.02.25.21252220, author = {Nathan J. Edwards and Rebecca Widrick and Justin Wilmes and Ben Breisch and Mike Gerschefske and Jon Sullivan and Richard Potember and Angelica Espinoza-Calvio}, title = {Reducing COVID-19 Airborne Transmission Risks on Public Transportation Buses: An Empirical Study on Aerosol Dispersion and Control}, elocation-id = {2021.02.25.21252220}, year = {2021}, doi = {10.1101/2021.02.25.21252220}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {This study is one of the first COVID-19 related bus studies to fully characterize cough aerosol dispersion and control in the highly turbulent real-world environment of driving regular bus routes on both a school bus and a transit bus. While several other bus studies have been conducted, they were limited to clinical contact tracing, simulation, or partial characterization of aerosol transmission in the passenger areas with constraint conditions. When considering the risk of transmission of SARS-CoV-2 (COVID-19) and other highly infectious airborne diseases, ground based public transportation systems are high-risk environments for airborne transmission particularly since social distancing of six feet is not practical on most buses. This study demonstrates that wearing of masks reduced the overall particle count released into the bus by an average of 50\% or more depending on mask quality and reduced the dispersion distance by several feet. The study also demonstrates an 84.36\% reduction in aerosol particles and an 80.28\% reduction in the mean aerosol residence time for some test cases. We conducted 84 experimental runs using nebulized 10\% sodium chloride and a mechanical exhalation simulator that resulted in 78.3 million data points and 124 miles of on-the-road testing. Our study not only captures the dispersion patterns using 28 networked particle counters, as well as quantifies the effectiveness of using on-board fans, opening of various windows, use of face coverings or masks, and the use of the transit bus HVAC system. This work also provides empirical observations of aerosol dispersion in a real-world turbulent air environment, which are remarkably different than many existing fluid dynamics simulations, and also offers substantial discussion on the implications for inclement weather conditions, driver safety, retrofit applications to improve bus air quality, and operational considerations for public transportation organizations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by independent research and development funding provided by the author{\textquoteright}s organization, The MITRE Corporation. Copyright 2021 The MITRE Corporation. ALL RIGHTS RESERVED. Approved for Public Release; Distribution Unlimited. Public Release Case Number 21-0157.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MITRE Institutional Review Board reviewed this study protocol, Quantifying Airborne Dispersion in Public Transportation, and determined that the activity is not human subjects research as defined by 45 CFR 46.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated from this study are available to U.S. national, state and regional agencies as well as healthcare systems on request to the corresponding author.}, URL = {https://www.medrxiv.org/content/early/2021/03/01/2021.02.25.21252220}, eprint = {https://www.medrxiv.org/content/early/2021/03/01/2021.02.25.21252220.full.pdf}, journal = {medRxiv} }